Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers

"1. Period 1 (single dose)~ * Day1: Placebo, Topical administered one drop to each eye (Once a day)~ * Day2: SJP002, Topical administered one drops to each eye (Once a day)~ * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"

"1. Period 1 (single dose)~ * Day1: Placebo, Topical administered one drop to each eye (Once a day)~ * Day2: Placebo, Topical administered one drops to each eye (Once a day)~ * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"